Aug 2026· Research Square· 0 citations· 38 references
Medicine
TL;DR
Genetic risk stratification revealed heterogeneous protein-AD associations and genotype-dependent proteomic pathways, including 94 newly identified proteins.
Abstract
Background Whether plasma protein associations with Alzheimer’s disease (AD) differ by genetic risk remains unclear. Methods We studied 18,212 UK Biobank participants aged ≥ 60 years with Olink Explore 3072 proteomic data, APOE genotypes, and AD polygenic risk scores. Protein-by-genetic risk interactions were screened, followed by genetic risk-stratified association and mediation analyses in Cox models. Results During 12.8 years of follow-up, 374 participants developed AD. APOE ε4 carriers had higher AD risk than non-carriers (HR = 7.79 [6.18–9.81]), with the greatest risk among ε4 homozygotes (HR = 17.73 [13.36–23.51]). Stratified analyses identified AD-associated proteins among APOE ε4 non-carriers (n = 85), ε4 carriers (n = 10), and low-, intermediate-, and high-AD-PRS groups (n = 10, 1, and 2, respectively), including 94 newly identified proteins. APOE protein, MENT, and GFAP mediated 34.49%, 25.01%, and 11.47% of the APOE ε4-AD association. Conclusions Genetic risk stratification revealed heterogeneous protein-AD associations and genotype-dependent proteomic pathways.
The results underscore the importance of investigating genetic architectures when assessing AD risk and call for larger, multi-center studies across the Middle East to elucidate the interplay between APOE variants and metabolic determinants of cognitive decline.
Ibrahim Labbad, Lama A. Youssef, Maha Rustom et al.· Journal of Alzheimer's Disea...· 0 citations
In this Indian cohort, APOE ε4 homozygosity reflects increased susceptibility and familial aggregation of AD but does not confer a more severe or distinct phenotype, suggesting ancestry- specific expression of APOE ε4 gene-dose effects.
Pratibha Vinod, C. Arampady, Somdatta Sen et al.· Neurodegenerative Disease Ma...· 0 citations
Understanding of the genetic architecture of AD in the context of its main genetic driver is improved, and APOE-stratified insights may help understand and overcome side effects, inform clinical trial enrollment strategies, and create the scientific basis for targeted, mechanism-driven therapies in neurodegenerative di...
J. Thomassen, H. Leonard, Brittany Ulms et al.· Nature Genetics· 0 citations
APOE
genotype is a very strong genetic risk factor for late-onset Alzheimer’s disease (AD). This relationship may involve mediation by common infections—several of which are also dementia risk factors. We investigated associations of
APOE
ε2 and ε4 carriage with serostatus and antibody titres to 14 common pathog...
R. Green, A. Fernández-Sanlés, Caterina Felici et al.· Scientific Reports· 0 citations
Attenuated associations in older-old adults may reflect survivor bias, while stronger associations in APOE ε4 carriers are consistent with gene-environment interactions, which are consistent with gene-environment interactions.
Yang Kong, Xian Li, Rui-Qian Guan et al.· Alzheimer Disease and Associ...· 0 citations
Findings support the use of biomarker-informed approaches to guide monitoring and therapeutic intervention in appropriately selected at-risk individuals before the onset of clinical symptoms and support the use of biomarker-informed approaches to guide monitoring and therapeutic intervention.
Yue-Xuan Xu, T. I. Gunasekaran, Yian Gu et al.· Lancet Neurology· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.